<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00348</drugbank-id>
  <drugbank-id>APRD01141</drugbank-id>
  <name>Nitisinone</name>
  <description>Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin.</description>
  <cas-number>104206-65-7</cas-number>
  <unii>K5BN214699</unii>
  <average-mass>329.2281</average-mass>
  <monoisotopic-mass>329.05110705</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.</indication>
  <pharmacodynamics>Hereditary tyrosinemia type 1 occurs due to a deficiency in fumarylacetoacetase (FAH), the final enzyme in the tyrosine catabolic pathway. Nitisinone inhibits catabolism of tyrosine by preventing the catabolic intermediates. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of HT-1.</pharmacodynamics>
  <mechanism-of-action>Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolyase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with hereditary tyrosinemia type 1 (HT-1), nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate.</mechanism-of-action>
  <toxicity>Side effects include elevated plasma levels of this amino acid, hepatic and liver failure.</toxicity>
  <metabolism/>
  <absorption>The capsule and liquid formulations are bioequivalent in both the plasma concentration-time curve and maximum plasma concentration (Cmax).</absorption>
  <half-life>~54 hours</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzoylcyclohexane-1,3-diones. These are alkyl-phenylketones where the alkyl group is a cyclohexane 1,3-dione.</description>
    <direct-parent>Benzoylcyclohexane-1,3-diones</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Carbonyl compounds</subclass>
    <alternative-parent>Alkyl fluorides</alternative-parent>
    <alternative-parent>Aryl alkyl ketones</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Beta-diketones</alternative-parent>
    <alternative-parent>Cyclic ketones</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Nitroaromatic compounds</alternative-parent>
    <alternative-parent>Nitrobenzenes</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic oxoazanium compounds</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Trifluoromethylbenzenes</alternative-parent>
    <substituent>1,3-dicarbonyl compound</substituent>
    <substituent>1,3-diketone</substituent>
    <substituent>Alkyl fluoride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Aryl alkyl ketone</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Benzoylcyclohexane-1,3-dione</substituent>
    <substituent>C-nitro compound</substituent>
    <substituent>Cyclic ketone</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Nitroaromatic compound</substituent>
    <substituent>Nitrobenzene</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitro compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxoazanium</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Trifluoromethylbenzene</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione</synonym>
    <synonym language="spanish" coder="inn">Nitisinona</synonym>
    <synonym language="english" coder="inn/usan">Nitisinone</synonym>
    <synonym language="latin" coder="inn">Nitisinonum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Mdk-nitisinone</name>
      <labeller>Mendelikabs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02457717</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mdk-nitisinone</name>
      <labeller>Mendelikabs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02457725</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mdk-nitisinone</name>
      <labeller>Mendelikabs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02457733</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mdk-nitisinone</name>
      <labeller>Mendelikabs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02470055</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nitisinone</name>
      <labeller>Novitium Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70954-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211041</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nitisinone</name>
      <labeller>Novitium Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70954-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211041</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nitisinone</name>
      <labeller>Novitium Pharma Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70954-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211041</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nitisinone</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-3020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211041</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nitisinone</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-3021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211041</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nitisinone</name>
      <labeller>Par Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0254-3022</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA211041</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nitisinone Tablets</name>
      <labeller>Cycle Pharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458616</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nitisinone Tablets</name>
      <labeller>Cycle Pharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458624</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nitisinone Tablets</name>
      <labeller>Cycle Pharmaceuticals Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458632</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-12-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nityr</name>
      <labeller>Cycle Pharmaceuticals Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>70709-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209449</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nityr</name>
      <labeller>Cycle Pharmaceuticals Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>70709-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209449</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nityr</name>
      <labeller>Cycle Pharmaceuticals Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>70709-000</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA209449</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>Rare Disease Therapeutics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66621-1002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-18</started-marketing-on>
      <ended-marketing-on>2015-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>Rare Disease Therapeutics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66621-1005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-18</started-marketing-on>
      <ended-marketing-on>2015-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>Rare Disease Therapeutics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66621-1010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-01-18</started-marketing-on>
      <ended-marketing-on>2015-07-31</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-204</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>4 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA206356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-105</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021232</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459698</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459701</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459728</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459736</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Orfadin</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02469693</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>4 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nityr</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nityr</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nityr</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Mdk-nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Mdk-nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Mdk-nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone Tablets</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone Tablets</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Orfadin</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Mdk-nitisinone</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
    <mixture>
      <name>Nitisinone Tablets</name>
      <ingredients>Nitisinone</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Apoteket Produktion and Laboratorier Ab</name>
      <url>http://www.apl.se</url>
    </packager>
    <packager>
      <name>Rare Disease Therapeutics Inc.</name>
      <url>http://www.raretx.com</url>
    </packager>
    <packager>
      <name>Swedish Orphan International Ab</name>
      <url>http://www.swedishorphan.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Rare disease therapeutics inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Orfadin 2 mg capsule</description>
      <cost currency="USD">61.74</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Orfadin 5 mg capsule</description>
      <cost currency="USD">154.34</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Orfadin 10 mg capsule</description>
      <cost currency="USD">308.68</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>4-Hydroxyphenylpyruvate Dioxygenase, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzoates</category>
      <mesh-id>D001565</mesh-id>
    </category>
    <category>
      <category>Cyclohexanes</category>
      <mesh-id>D003510</mesh-id>
    </category>
    <category>
      <category>Cycloparaffins</category>
      <mesh-id>D003516</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2C9 Inhibitors</category>
      <mesh-id>D065688</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inhibitors</category>
      <mesh-id>D065607</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Hydroxyphenylpyruvate Dioxygenase Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ketones</category>
      <mesh-id>D007659</mesh-id>
    </category>
    <category>
      <category>Other Miscellaneous Therapeutic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Various Alimentary Tract and Metabolism Products</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength>4 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Oral</route>
      <strength>4 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AX04">
      <level code="A16AX">Various alimentary tract and metabolism products</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>92:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00348.pdf?1265922809</fda-label>
  <patents>
    <patent>
      <number>5550165</number>
      <country>United States</country>
      <approved>1996-08-27</approved>
      <expires>2013-08-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9301932</number>
      <country>United States</country>
      <approved>2016-04-05</approved>
      <expires>2033-02-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10328029</number>
      <country>United States</country>
      <approved>2019-06-25</approved>
      <expires>2035-01-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.06</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>8.11e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>nitisinone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>329.2281</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>329.05110705</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H10F3NO5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OUBCNLGXQFSTLU-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>97.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>72.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>26.74</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>2.71</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-7.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>1.6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22811</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>50378</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>115355</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507380</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>103195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50088804</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164777037</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000774</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Nitisinone</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1337</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/orfadin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/nitisinone.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000455</id>
      <name>4-hydroxyphenylpyruvate dioxygenase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A4655</ref-id>
            <pubmed-id>15931360</pubmed-id>
            <citation>Fisher AA, Davis MW: Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. 2004 Nov;2(4):209-15.</citation>
          </article>
          <article>
            <ref-id>A4656</ref-id>
            <pubmed-id>14668946</pubmed-id>
            <citation>Yang DY: 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003 Oct;16(8):493-6.</citation>
          </article>
          <article>
            <ref-id>A4657</ref-id>
            <pubmed-id>12142814</pubmed-id>
            <citation>Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J: Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. J Pediatr Gastroenterol Nutr. 2002 Jul;35(1):73-8.</citation>
          </article>
          <article>
            <ref-id>A4658</ref-id>
            <pubmed-id>15931605</pubmed-id>
            <citation>Suwannarat P, O'Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-Kupfer MI, Rubin BI, Tsilou E, Gerber LH, Gahl WA: Use of nitisinone in patients with alkaptonuria. Metabolism. 2005 Jun;54(6):719-28.</citation>
          </article>
          <article>
            <ref-id>A4659</ref-id>
            <pubmed-id>18422479</pubmed-id>
            <citation>Santra S, Baumann U: Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36. doi: 10.1517/14656566.9.7.1229.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P32754" source="Swiss-Prot">
        <name>4-hydroxyphenylpyruvate dioxygenase</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Key enzyme in the degradation of tyrosine.</specific-function>
        <gene-name>HPD</gene-name>
        <locus>12q24-qter</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.01</theoretical-pi>
        <molecular-weight>44934.12</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5147</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HPD</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U29895</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3860238</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P32754</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HPPD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.13.11.27</synonym>
          <synonym>4-hydroxyphenylpyruvic acid oxidase</synonym>
          <synonym>4HPPD</synonym>
          <synonym>HPD</synonym>
          <synonym>HPPDase</synonym>
          <synonym>PPD</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037021|4-hydroxyphenylpyruvate dioxygenase
MTTYSDKGAKPERGRFLHFHSVTFWVGNAKQAASFYCSKMGFEPLAYRGLETGSREVVSH
VIKQGKIVFVLSSALNPWNKEMGDHLVKHGDGVKDIAFEVEDCDYIVQKARERGAKIMRE
PWVEQDKFGKVKFAVLQTYGDTTHTLVEKMNYIGQFLPGYEAPAFMDPLLPKLPKCSLEM
IDHIVGNQPDQEMVSASEWYLKNLQFHRFWSVDDTQVHTEYSSLRSIVVANYEESIKMPI
NEPAPGKKKSQIQEYVDYNGGAGVQHIALKTEDIITAIRHLRERGLEFLSVPSTYYKQLR
EKLKTAKIKVKENIDALEELKILVDYDEKGYLLQIFTKPVQDRPTLFLEVIQRHNHQGFG
AGNFNSLFKAFEEEQNLRGNLTNMETNGVVPGM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010319|4-hydroxyphenylpyruvate dioxygenase (HPD)
ATGGGCTTTGAACCTCTAGCCTACAGGGGCCTGGAGACCGGTTCCCGGGAGGTGGTCAGC
CATGTAATCAAACAAGGGAAGATTGTGTTTGTCCTCTCCTCAGCGCTCAACCCCTGGAAC
AAAGAGATGGGCGATCACCTGGTGAAACACGGTGACGGAGTGAAGGACATTGCGTTCGAG
GTGGAAGATTGTGACTACATCGTGCAGAAAGCACGGGAACGGGGCGCCAAAATCATGCGG
GAGCCCTGGGTAGAGCAAGACAAGTTTGGGAAGGTGAAGTTTGCTGTGCTGCAGACGTAT
GGGGACACCACACACACCCTGGTGGAGAAGATGAACTACATCGGCCAATTCTTGCCTGGA
TATGAGGCCCCAGCGTTCATGGACCCCCTACTTCCTAAACTGCCCAAATGCAGTCTGGAG
ATGATCGACCACATTGTGGGAAACCAGCCTGATCAGGAGATGGTGTCCGCCTCCGAATGG
TACCTGAAAAACCTGCAGTTCCACCGCTTCTGGTCCGTGGATGACACGCAGGTGCACACG
GAATATAGCTCTCTGCGATCCATTGTGGTGGCCAACTATGAAGAGTCCATCAAGATGCCC
ATCAATGAGCCAGCGCCTGGCAAGAAGAAGTCCCAGATCCAGGAATATGTGGACTATAAC
GGGGGCGCTGGGGTCCAGCACATCGCTCTCAAGACCGAAGACATCATCACAGCGATTCGC
CACTTGAGAGAGAGAGGCCTGGAGTTCTTATCTGTTCCCTCCACGTACTACAAACAACTG
CGGGAGAAGCTGAAGACGGCCAAGATCAAGGTGAAGGAGAACATTGATGCCCTGGAGGAG
CTGAAAATCCTGGTGGACTACGACGAGAAAGGCTACCTCCTGCAGATCTTCACCAAACCG
GTGCAGGACCGGCCCACGCTCTTCCTGGAAGTCATCCAGCGCCACAACCACCAGGGTTTT
GGAGCCGGCAACTTCAACTCACTGTTCAAGGCTTTCGAGGAGGAGCAGAACCTGCGGGGT
AACCTCACCAACATGGAGACCAATGGGGTGGTGCCCGGCATGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00903</identifier>
            <name>Glyoxalase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4-hydroxyphenylpyruvate dioxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular nitrogen compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>L-phenylalanine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tyrosine catabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>